Hypoparathyroidism Treatment Market By Drug Class, Route of Administration and Distribution Channels - Global Industry Analysis & Forecast to 2027
Published On : December 2018 Pages : 140 Category: Pharma & Healthcare Report Code : FB122015
Hypoparathyroidism Treatment Market By Drug Class (Vitamin D Analogue, Parathyroid Hormone, Calcium Supplements) Route of Administration (Parenteral, Oral) Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Sales) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Hypoparathyroidism Treatment Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. The uncommon condition named hypoparathyroidism includes the decrease in the activity parathyroid organs. The most well-known way a patient can experience the ill effects of hypoparathyroidism is after the parathyroid organs get expelled or harmed amid medical procedure. It is a condition of low parathyroid hormone discharge and can cause an extreme drop in calcium levels in the blood and also elevated amounts of phosphorus in the blood. Side effects for hypoparathyroidism run from mellow shivering in fingers, hands, or the mouth, to more genuine and agonizing muscle cramps. Exceptionally uncommon indications displayed by patients incorporate spasms and outrageous muscle cramping of the entire body.
Drivers and Restraints
The developing screening rates, expanding number of thoracic medical procedures and occurrence of disease are anticipated to be the prime elements driving the development of the hypoparathyroidism treatment market. Thyroid or neck surgery is related with hypoparathyroidism, inferable from harm to the parathyroid organs. The quantity of thyroidectomies in the U.S. reflects 39% expansion from 2007 to 2017. Expanding interests in the innovative work combined with the advancement of biologics is foreseen to produce energy and development opportunities for the hypoparathyroidism treatment market.
Regional Insights
North America will be the potential market for the players as there is major demand for the product, and the players are also coming with new product with proper FDA approval.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- F. Hoffmann-La Roche Ltd
- WCCT GLOBAL INC
- Novartis AG
- Shire-NPS Pharmaceuticals, Inc
- EnteraBio Ltd
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline plc
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Hypoparathyroidism Treatment Market, By Drug Class, Estimates and Forecast, 2017-2027($Billion)
o Vitamin D Analogue
o Parathyroid Hormone
o Calcium Supplements
· Hypoparathyroidism Treatment Market, By Route of Administration, Estimates and Forecast, 2017-2027($Billion)
o Parenteral
o Oral
· Hypoparathyroidism Treatment Market, By Distribution Channels, Estimates and Forecast, 2017-2027($Billion)
o Hospital Pharmacy
o Retail Pharmacy
o Online Sales
· Hypoparathyroidism Treatment Market, By Region, Estimates and Forecast, 2017-2027($Billion)
o North America
§ North America Hypoparathyroidism Treatment Market, By Country
o U.S. Hypoparathyroidism Treatment Market
o Canada Hypoparathyroidism Treatment Market
o Mexico Hypoparathyroidism Treatment Market
o Europe
§ Europe Hypoparathyroidism Treatment Market, By Country
o Germany Hypoparathyroidism Treatment Market
o UK Hypoparathyroidism Treatment Market
o France Hypoparathyroidism Treatment Market
o Russia Hypoparathyroidism Treatment Market
o Italy Hypoparathyroidism Treatment Market
o Rest of Europe Hypoparathyroidism Treatment Market
o Asia-Pacific
§ Asia-Pacific Hypoparathyroidism Treatment Market, By Country
o China Hypoparathyroidism Treatment Market
o Japan Hypoparathyroidism Treatment Market
o South Korea Hypoparathyroidism Treatment Market
o India Hypoparathyroidism Treatment Market
o Southeast Asia Hypoparathyroidism Treatment Market
o Rest of Asia-Pacific Hypoparathyroidism Treatment Market
o South America
§ South America Hypoparathyroidism Treatment Market
o Brazil Hypoparathyroidism Treatment Market
o Argentina Hypoparathyroidism Treatment Market
o Columbia Hypoparathyroidism Treatment Market
o Rest of South America Hypoparathyroidism Treatment Market
o Middle East and Africa
§ Middle East and Africa Hypoparathyroidism Treatment Market
o Saudi Arabia Hypoparathyroidism Treatment Market
o UAE Hypoparathyroidism Treatment Market
o Egypt Hypoparathyroidism Treatment Market
o Nigeria Hypoparathyroidism Treatment Market
o South Africa Hypoparathyroidism Treatment Market
o Rest of MEA Hypoparathyroidism Treatment Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Hypoparathyroidism Treatment Market, By Drug Class
5.1. Introduction
5.2. Global Hypoparathyroidism Treatment Revenue and Market Share by Drug Class (2017-2027)
5.2.1. Global Hypoparathyroidism Treatment Revenue and Revenue Share by Drug Class (2017-2027)
5.3. Vitamin D Analogue
5.3.1. Global Vitamin D Analogue Revenue and Growth Rate (2017-2027)
5.4. Parathyroid Hormone
5.4.1. Global Parathyroid Hormone Revenue and Growth Rate (2017-2027)
5.5. Calcium Supplements
5.5.1. Global Calcium Supplements Revenue and Growth Rate (2017-2027)
6. Hypoparathyroidism Treatment Market, By Route Of Administration
6.1. Introduction
6.2. Global Hypoparathyroidism Treatment Revenue and Market Share by Route Of Administration (2017-2027)
6.2.1. Global Hypoparathyroidism Treatment Revenue and Revenue Share by Route Of Administration (2017-2027)
6.3. Parenteral
6.3.1. Global Parenteral Revenue and Growth Rate (2017-2027)
6.4. Oral
6.4.1. Global Oral Revenue and Growth Rate (2017-2027)
7. Hypoparathyroidism Treatment Market, By Distribution Channels
7.1. Introduction
7.2. Global Hypoparathyroidism Treatment Revenue and Market Share by Distribution Channels (2017-2027)
7.2.1. Global Hypoparathyroidism Treatment Revenue and Revenue Share by Distribution Channels (2017-2027)
7.3. Hospital Pharmacy
7.3.1. Global Hospital Pharmacy Revenue and Growth Rate (2017-2027)
7.4. Retail Pharmacy
7.4.1. Global Retail Pharmacy Revenue and Growth Rate (2017-2027)
7.5. Online Sales
7.5.1. Global Online Sales Revenue and Growth Rate (2017-2027)
8. Hypoparathyroidism Treatment Market, By Region
8.1. Introduction
8.2. Global Hypoparathyroidism Treatment Revenue and Market Share by Regions
8.2.1. Global Hypoparathyroidism Treatment Revenue by Regions (2017-2027)
8.3. North America Hypoparathyroidism Treatment by Countries
8.3.1. North America Hypoparathyroidism Treatment Revenue and Growth Rate (2017-2027)
8.3.2. North America Hypoparathyroidism Treatment Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Hypoparathyroidism Treatment by Countries
8.4.1. Europe Hypoparathyroidism Treatment Revenue and Growth Rate (2017-2027)
8.4.2. Europe Hypoparathyroidism Treatment Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Hypoparathyroidism Treatment by Countries
8.5.1. Asia-Pacific Hypoparathyroidism Treatment Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Hypoparathyroidism Treatment Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Hypoparathyroidism Treatment by Countries
8.6.1. South America Hypoparathyroidism Treatment Revenue and Growth Rate (2017-2027)
8.6.2. South America Hypoparathyroidism Treatment Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Hypoparathyroidism Treatment by Countries
8.7.1. Middle East and Africa Hypoparathyroidism Treatment Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Hypoparathyroidism Treatment Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. F. Hoffmann-La Roche Ltd
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Revenue and Market Share
9.2. WCCT GLOBAL INC
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Revenue and Market Share
9.3. Novartis AG
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Revenue and Market Share
9.4. Shire-NPS Pharmaceuticals, Inc
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Revenue and Market Share
9.5. EnteraBio Ltd
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Revenue and Market Share
9.6. Takeda Pharmaceutical Company Limited
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Revenue and Market Share
9.7. GlaxoSmithKline plc
9.7.1. Business Overview
9.7.2. Service Portfolio
9.7.3. Strategic Developments
9.7.4. Revenue and Market Share
10. Global Hypoparathyroidism Treatment Market Competition, by Manufacturer
10.1. Global Hypoparathyroidism Treatment Revenue and Market Share by Manufacturer (2017-2017)
10.2. Global Hypoparathyroidism Treatment Price By Region (2017-2017)
10.3. Top 5 Hypoparathyroidism Treatment Manufacturer Market Share
10.4. Market Competition Trend
11. Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.1. Global Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
11.2. Hypoparathyroidism Treatment Market Forecast by Regions (2017-2027)
11.2.1. North America Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.1.1. United States Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.1.2. Canada Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.1.3. Mexico Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.2. Europe Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.2.1. Germany Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.2.2. France Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.2.3. UK Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.2.4. Russia Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.2.5. Italy Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.2.6. Rest of Europe Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.3. Asia-Pacific Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.3.1. China Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.3.2. Japan Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.3.3. Korea Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.3.4. India Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.3.5. Southeast Asia Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.3.6. Rest of Asia-Pacific Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.4. South America Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.4.1. Brazil Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.4.2. Argentina Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.4.3. Columbia Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.4.4. Rest of South America Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.5. Middle East and Africa Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.5.1. Saudi Arabia Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.5.2. United Arab Emirates Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.5.3. Egypt Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.5.4. Nigeria Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.5.5. South Africa Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.5.6. Turkey Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.2.5.7. Rest of Middle East and Africa Hypoparathyroidism Treatment Market Forecast (2017-2027)
11.3. Hypoparathyroidism Treatment Market Forecast by Drug Class (2017-2027)
11.3.1. Hypoparathyroidism Treatment Forecast by Drug Class (2017-2027)
11.3.2. Hypoparathyroidism Treatment Market Share Forecast by Drug Class (2017-2027)
11.4. Hypoparathyroidism Treatment Market Forecast by Route Of Administration (2017-2027)
11.4.1. Hypoparathyroidism Treatment Forecast by Route Of Administration (2017-2027)
11.4.2. Hypoparathyroidism Treatment Market Share Forecast by Route Of Administration (2017-2027)
11.5. Hypoparathyroidism Treatment Market Forecast by Distribution Channels (2017-2027)
11.5.1. Hypoparathyroidism Treatment Forecast by Distribution Channels (2017-2027)
11.5.2. Hypoparathyroidism Treatment Market Share Forecast by Distribution Channels (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Hypoparathyroidism Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Hypoparathyroidism Treatment Revenue and Revenue Share by Drug Class (2017-2018)
Figure Global Vitamin D Analogue Revenue and Growth Rate (2017-2018)
Figure Global Parathyroid Hormone Revenue and Growth Rate (2017-2018)
Figure Global Calcium Supplements Revenue and Growth Rate (2017-2018)
Table Global Hypoparathyroidism Treatment Revenue and Revenue Share by Route Of Administration (2017-2018)
Figure Global Parenteral Revenue and Growth Rate (2017-2018)
Figure Global Oral Revenue and Growth Rate (2017-2018)
Table Global Hypoparathyroidism Treatment Revenue and Revenue Share by Distribution Channels (2017-2018)
Figure Global Hospital Pharmacy Revenue and Growth Rate (2017-2018)
Figure Global Retail Pharmacy Revenue and Growth Rate (2017-2018)
Figure Global Online Sales Revenue and Growth Rate (2017-2018)
Table Global Hypoparathyroidism Treatment Revenue by Regions (2017-2018)
Figure North America Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure North America Hypoparathyroidism Treatment Revenue and Growth Rate (2017-2018)
Figure North America Hypoparathyroidism Treatment by Countries (2017-2018)
Figure North America Hypoparathyroidism Treatment Revenue (Million USD) by Countries (2017-2018)
Figure United States Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure United States Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Canada Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Mexico Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Europe Hypoparathyroidism Treatment Revenue and Growth Rate (2017-2018)
Figure Europe Hypoparathyroidism Treatment by Countries (2017-2018)
Figure Europe Hypoparathyroidism Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Germany Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Germany Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure France Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure UK Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Russia Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Italy Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Rest of Europe Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Asia-Pacific Hypoparathyroidism Treatment Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Hypoparathyroidism Treatment by Countries (2017-2018)
Figure Asia-Pacific Hypoparathyroidism Treatment Revenue (Million USD) by Countries (2017-2018)
Figure China Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure China Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Japan Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Korea Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure India Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Southeast Asia Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure South America Hypoparathyroidism Treatment Revenue and Growth Rate (2017-2018)
Figure South America Hypoparathyroidism Treatment by Countries (2017-2018)
Figure South America Hypoparathyroidism Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Brazil Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Argentina Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Columbia Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Rest of South America Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Middle East and Africa Hypoparathyroidism Treatment Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Hypoparathyroidism Treatment by Countries (2017-2018)
Figure Middle East and Africa Hypoparathyroidism Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Saudi Arabia Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure United Arab Emirates Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Egypt Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Nigeria Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure South Africa Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Turkey Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Hypoparathyroidism Treatment Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Table F. Hoffmann-La Roche Ltd Hypoparathyroidism Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table WCCT GLOBAL INC Hypoparathyroidism Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Novartis AG Hypoparathyroidism Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Shire-NPS Pharmaceuticals, Inc Hypoparathyroidism Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table EnteraBio Ltd Hypoparathyroidism Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Takeda Pharmaceutical Company Limited Hypoparathyroidism Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Table GlaxoSmithKline plc Hypoparathyroidism Treatment Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Hypoparathyroidism Treatment Market Share by Manufacturer
Figure Global Hypoparathyroidism Treatment Revenue and Market Share by Manufacturer
Table Global Hypoparathyroidism Treatment Price by Region (2017-2017)
Figure Top 5 Hypoparathyroidism Treatment Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Hypoparathyroidism Treatment Revenue (Millions USD) and Growth Rate (2018-2025)
Table Hypoparathyroidism Treatment Market Forecast by Regions (2018-2025)
Figure North America Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure United States Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Canada Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Mexico Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Europe Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Germany Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure France Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure UK Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Russia Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Italy Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Rest of Europe Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Asia-Pacific Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure China Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Japan Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Korea Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure India Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Southeast Asia Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure South America Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Brazil Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Argentina Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Columbia Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Rest of South America Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Middle East and Africa Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Saudi Arabia Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure United Arab Emirates Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Egypt Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Nigeria Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure South Africa Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Turkey Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Hypoparathyroidism Treatment Market Forecast (2018-2025)
Figure Global Hypoparathyroidism Treatment Forecast by Drug Class (2018-2025)
Figure Global Hypoparathyroidism Treatment Market Share Forecast by Drug Class (2018-2025)
Figure Global Hypoparathyroidism Treatment Forecast by Drug Class (2018-2025)
Figure Global Hypoparathyroidism Treatment Forecast by Route Of Administration (2018-2025)
Figure Global Hypoparathyroidism Treatment Market Share Forecast by Route Of Administration (2018-2025)
Figure Global Hypoparathyroidism Treatment Forecast by Route Of Administration (2018-2025)
Figure Global Hypoparathyroidism Treatment Forecast by Distribution Channels (2018-2025)
Figure Global Hypoparathyroidism Treatment Market Share Forecast by Distribution Channels (2018-2025)
Figure Global Hypoparathyroidism Treatment Forecast by Distribution Channels (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|